Granted Patent B2

US 9,884,113 · App. 14/729,408 · Granted Feb 6, 2018

Inventors: Ralph Leon Biemans (Rixensart, BE); Nathalie Marie-Josephe Garcon (Rixensart, BE); Philippe Vincent Hermand (Rixensart, BE); Jan Poolman (Haarlem, NL); Marcelle Paulette Van Mechelen (Rixensart, BE)

Assignee: GlaxoSmithKline Biologicals, SA

A61K39/385A61K39/092A61K47/646A61K47/6415A61K2039/545A61K2039/55A61K2039/555A61K2039/55566A61K2039/575A61K2039/6031A61K2039/6037A61K2039/6068A61K2039/6087A61K2039/62A61K2039/627A61K2039/70

Abstract

Claims (13)

1. A method of immunising a human host against disease caused by Streptococcus pneumoniae serotype 19A infection comprising the step of administering to the host an immunoprotective dose of a Streptococcus pneumoniae immunogenic composition comprising 10 or more capsular saccharides from different S. pneumoniae serotypes conjugated to 3 or more different carrier proteins, wherein the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT); serotype 18C capsular saccharide conjugated to tetanus toxoid (TT); and serotype 1, 4, 5, 6B, 7F, 9V, 14 and 23F capsular saccharide conjugated to protein D from Haemophilus influenzae but does not comprise capsular saccharide from serotype 19A.

2. The method of claim 1 wherein the serotype 19F capsular saccharide is the only saccharide in the immunogenic composition conjugated to diphtheria toxoid.

3. The method of claim 1 wherein the immunogenic composition comprises serotype 19F capsular saccharide directly conjugated to the carrier protein.

4. The method of claim 1 wherein the immunogenic composition comprises serotype 19F capsular saccharide conjugated to the carrier protein via a linker.

5. The method of claim 1 wherein the immunogenic composition comprises serotype 19F capsular saccharide conjugated to the carrier protein using 1-cyano-4-dimethylamino pyridinium tetrafluoroborate (CDAP) chemistry.

6. The method of claim 1 wherein the ratio of carrier protein to serotype 19F capsular saccharide in the immunogenic composition is between 5:1 and 1:5.

7. The method of claim 1 wherein the average size of the serotype 19F capsular saccharide in the immunogenic composition is between 100-750 kDa.

8. The method of claim 1 wherein the dose of the serotype 19F saccharide conjugate in the immunogenic composition is between 1 and 10 μg of saccharide.

9. The method of claim 1 wherein the immunogenic composition comprises 4 different carrier proteins.

10. The method of claim 1 wherein the 3 or more different carrier proteins in the immunogenic composition are selected from the group consisting of diphtheria toxoid (DT), DT CRM 197 (a DT mutant), tetanus toxoid (TT), Fragment C of TT, dPly, PhtA, PhtB, PhtD, PhtE, PhtDE, OmpC, PorB and Haemophilus influenzae Protein D.

11. The method of claim 1 wherein the immunogenic composition comprises capsular saccharide 18C conjugated to tetanus toxoid, wherein 18C is the only capsular saccharide in the composition conjugated to tetanus toxoid.

12. The method of claim 1 , wherein the average size of the serotype 18C capsular saccharide in the immunogenic compositions is between 50-550 kDa.

13. The method of claim 4 wherein the immunogenic composition comprises serotype 19F capsular saccharide conjugated to the linker using 1-cyano-4-dimethylamino pyridinium tetrafluoroborate (CDAP) chemistry.

Assignments (1)

Priority Claims (9)

Continuity (3)